Summary
- Profile Type
- Business request
- POD Reference
- BRFR20251010013
- Term of Validity
- 13 October 2025 - 13 October 2026
- Company's Country
- France
- Type of partnership
- Supplier agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A French start-up is developing therapeutic molecules to protect the heart and other organs from cell death after injury. Following a successful proof-of-concept study showing the efficacy of the lead molecule for the treatment of myocardial infarction, the company is now seeking partners for preclinical regulatory evaluation (toxicology, safety, large species), formulation of the molecule, and clinical trial design.
- Full Description
-
A French start-up is developing cutting-edge therapeutic molecules targeting cell death mechanisms triggered by oxygen deprivation in organs, particularly during acute myocardial infarction.
Management of patients by the interventional cardiologist consists of reopening the coronary artery occluded during the heart attack. Unfortunately, instead of providing only benefits to save the patients, the sudden influx of oxygen can paradoxically activate cell death in vulnerable heart tissue. The company’s therapeutic innovation lies in inhibiting these harmful adverse effects, offering protection not only to the heart but also to other organs affected by ischemic injury, such as in stroke or organ transplantation. A proof-of-concept study has already demonstrated the efficacy of the lead molecule in treating myocardial infarction.
The start-up is now seeking European partners to perform preclinical regulatory evaluation (toxicology, safety, large species), formulation of the therapeutic molecule, and clinical design. Only suppliers that are capable of contributing to the development of a blockbuster drug will be considered. High standards in quality control are also essential for subcontracting. - Technical Specification or Expertise Sought
-
Partner for the experiment on a large animal model: The partner, a service provider or a platform, should have strong expertise in ischemia-reperfusion injury in the pig model and must have experience in large animal surgery with a protocol and experimental setup similar to that of the clinic (angioplasty balloon, MRI). To do this, he must have participated in several preclinical studies for big pharma that have provided validation (publication, medicine development, patent, etc.). The protocol used for evaluating the lead molecule should mimic the procedure used in the catheter laboratory by an interventional cardiologist.
Partner for regulatory pre-clinical studies: The partner, a service provider accepted by the FDA/EMA, must have expertise in the analysis of a peptide-based molecule for pharmacological and toxicity (genetic or general) studies.
Partner for IND and clinical trial: The partner, a service provider accepted by the FDA/EMA, must have expertise in parallel interaction between the EMA and FDA to obtain the required authorization to perform clinical trials.
Partner for drug formulation: The partner, a service provider, must have expertise in pre-formulation characterization studies, including accelerated stability (stress) studies, stability-indicating analytical method development, and other physicochemical characterizations designed to pinpoint potential product candidate stability problems and enable formulation optimization. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR status
- IPR granted
Partner Sought
- Expected Role of a Partner
-
The partner must be a service provider. It must have quality certification in its field, particularly regarding preclinical regulatory requirements:
Experimentation on a large animal model: The partner should have strong expertise in ischemia-reperfusion injury in the pig model and must be experienced in large animal surgery with a protocol and experimental setup similar to that of the clinic. To do this, he must have participated in several preclinical studies for big pharma that have provided validation (publication, medicine development, patent, etc.). The protocol used for evaluating the lead molecule should mimic the procedure used in the catheterization laboratory by an interventional cardiologist.
Regulatory pre-clinical studies: The partner, a service provider accepted by the FDA/EMA, must have the expertise in the analysis of a peptide-based molecule for pharmacological and toxicity (genetic or general) studies.
IND (Investigational New Drug) and clinical trial: The partner, a service provider accepted by the FDA/EMA, must have expertise in parallel interaction between the EMA and FDA to obtain the required authorization to perform clinical trials.
Drug formulation: The partner, acting as a service provider, must demonstrate expertise in pre-formulation characterization studies, including accelerated stability (stress) testing, the development of stability-indicating analytical methods, and various physicochemical characterizations aimed at identifying potential stability issues in the product candidate and supporting formulation optimization. - Type and Size of Partner
- SME 50 - 249
- Big company
- SME 11-49
- Type of partnership
- Supplier agreement
Dissemination
- Technology keywords
- 06001002 - Clinical Research, Trials
- 06001015 - Pharmaceutical Products / Drugs
- 06001011 - Heart and blood circulation illnesses
- Market keywords
- 09003001 - Engineering services
- 05005022 - Other clinical medicine
- Sector Groups Involved
- Health
- Targeted countries
- Afghanistan
- Aland Islands
- Albania
- Algeria
- American Samoa
- Andorra
- Angola
- Anguilla
- Antarctica
- Antigua and Barbuda
- Argentina
- Armenia
- Aruba
- Australia
- Austria
- Azerbaijan
- Bahamas
- Bahrain
- Bangladesh
- Barbados
- Belarus
- Belgium
- Belize
- Benin
- Bermuda
- Bhutan
- Bolivia
- Bonaire, Saint Eustatius and Saba
- Bosnia and Herzegovina
- Botswana
- Bouvet Island
- Brazil
- British Indian Ocean Territory
- British Virgin Islands
- Brunei
- Bulgaria
- Burkina Faso
- Burundi
- Cabo Verde
- Cambodia
- Cameroon
- Canada
- Cayman Islands
- Central African Republic
- Chad
- Chile
- China
- Christmas Island
- Cocos Islands
- Colombia
- Comoros
- Cook Islands
- Costa Rica
- Croatia
- Cuba
- Curacao
- Cyprus
- Czechia
- Democratic Republic of the Congo
- Denmark
- Djibouti
- Dominica
- Dominican Republic
- Ecuador
- Egypt
- El Salvador
- Equatorial Guinea
- Eritrea
- Estonia
- Eswatini
- Ethiopia
- Falkland Islands
- Faroe Islands
- Fiji
- Finland
- France
- French Guiana
- French Polynesia
- French Southern Territories
- Gabon
- Gambia
- Georgia
- Germany
- Ghana
- Gibraltar
- Greece
- Greenland
- Grenada
- Guadeloupe
- Guam
- Guatemala
- Guernsey
- Guinea
- Guinea-Bissau
- Guyana
- Haiti
- Heard Island and McDonald Islands
- Honduras
- Hong Kong
- Hungary
- Iceland
- India
- Indonesia
- Iran
- Iraq
- Ireland
- Isle of Man
- Israel
- Italy
- Ivory Coast
- Jamaica
- Japan
- Jersey
- Jordan
- Kazakhstan
- Kenya
- Kiribati
- Kosovo
- Kuwait
- Kyrgyzstan
- Laos
- Latvia
- Lebanon
- Lesotho
- Liberia
- Libya
- Liechtenstein
- Lithuania
- Luxembourg
- Macao
- Madagascar
- Malawi
- Malaysia
- Maldives
- Mali
- Malta
- Marshall Islands
- Martinique
- Mauritania
- Mauritius
- Mayotte
- Mexico
- Micronesia
- Moldova
- Monaco
- Mongolia
- Montenegro
- Montserrat
- Morocco
- Mozambique
- Myanmar
- Namibia
- Nauru
- Nepal
- Netherlands
- Netherlands Antilles
- New Caledonia
- Nicaragua
- Niger
- Nigeria
- Niue
- Norfolk Island
- North Korea
- North Macedonia
- Northern Mariana Islands
- Norway
- Oman
- Pakistan
- Palau
- Palestinian Territory
- Panama
- Papua New Guinea
- Paraguay
- Peru
- Philippines
- Pitcairn
- Poland
- Portugal
- Puerto Rico
- Qatar
- Republic of the Congo
- Reunion
- Romania
- Russia
- Rwanda
- Saint Barthelemy
- Saint Helena
- Saint Kitts and Nevis
- Saint Lucia
- Saint Martin
- Saint Pierre and Miquelon
- Saint Vincent and the Grenadines
- Samoa
- San Marino
- Sao Tome and Principe
- Saudi Arabia
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Singapore
- Sint Maarten
- Slovakia
- Slovenia
- Solomon Islands
- Somalia
- South Africa
- South Georgia and the South Sandwich Islands
- South Korea
- South Sudan
- Spain
- Sri Lanka
- Sudan
- Suriname
- Svalbard and Jan Mayen
- Sweden
- Switzerland
- Syria
- Taiwan
- Tajikistan
- Tanzania
- Thailand
- Timor Leste
- Togo
- Tokelau
- Tonga
- Trinidad and Tobago
- Tunisia
- Turkey
- Turkmenistan
- Turks and Caicos Islands
- Tuvalu
- U.S. Virgin Islands
- Uganda
- Ukraine
- United Arab Emirates
- United Kingdom
- United States
- United States Minor Outlying Islands
- Uruguay
- Uzbekistan
- Vanuatu
- Vatican
- Venezuela
- Vietnam
- Wallis and Futuna
- Western Sahara
- Yemen
- Zambia
- Zimbabwe